Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04193293
Recruitment Status : Suspended (Patient Recruitment)
First Posted : December 10, 2019
Last Update Posted : March 17, 2021
Sponsor:
Information provided by (Responsible Party):
SecuraBio

Brief Summary:
This study will assess the safety and preliminary efficacy of duvelisib in combination with pembrolizumab in subjects with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

Condition or disease Intervention/treatment Phase
Head and Neck Squamous Cell Carcinoma Drug: duvelisib Biological: pembrolizumab Phase 1 Phase 2

Detailed Description:
This is a multicenter, non-randomized, open-label Phase 1b/2 study designed to evaluate safety and tolerability and preliminary efficacy of duvelisib in combination with pembrolizumab in subjects with R/M HNSCC who are eligible for pembrolizumab monotherapy based on the current pembrolizumab prescribing information.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b/2 Study of Duvelisib in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Cancer
Actual Study Start Date : February 25, 2020
Actual Primary Completion Date : November 15, 2020
Estimated Study Completion Date : April 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Duvelisib BID + Pembrolizumab q3w

Stage 1: Duvelisib BID for 1 week followed by combination therapy with duvelisib BID + pembrolizumab q3w. (Cycle 1 will be 4 weeks consisting of the 1-week duvelisib monotherapy lead-in period followed by 1 dose of pembrolizumab in combination with 3 additional weeks of continuous dosing of duvelisib. Subsequent cycles will be 3 weeks .)

Stage 2: Duvelisib BID + pembrolizumab q3w in 3 week cycles.

Drug: duvelisib
PI3K Inhibitor
Other Names:
  • VS-0145
  • Copiktra

Biological: pembrolizumab
Immunotherapy (PD-1 inhibitor)
Other Names:
  • PD-1 inhibitor
  • anti-PD-1
  • Keytruda




Primary Outcome Measures :
  1. Stage 1: Number of participants with dose-limiting toxicities (DLTs) [ Time Frame: 4 weeks or 28 days ]
    Number of participants with dose-limiting toxicities (DLTs)

  2. Stage 1: Number of participants with treatment-emergent adverse events. [ Time Frame: 6 months ]
    Number of participants with treatment-emergent adverse events as assessed by CTCAE v5.as a measure of safety and tolerability of duvelisib in combination with pembrolizumab

  3. Stage 1 & 2 Combined Primary Objective: Overall response rate (ORR) [ Time Frame: Up to 2 years ]
    Proportion of subjects achieving complete response (CR) or partial response (PR) according to RECIST v 1.1


Secondary Outcome Measures :
  1. Stage 1 Unique Secondary Objective: ORR [ Time Frame: Until documented PD, unacceptable toxicity, discontinuation criteria are met, withdrawal, or death. Up to 2 years. ]
    Proportion of subjects achieving complete CR or PR according to RECIST v 1.1

  2. Stage 1 & 2 Combined Secondary Objective: Duration of response (DOR) [ Time Frame: From first response until documented PD. Up to 2 years. ]
    Time from response ≥ PR to documented disease progression according to RECIST v 1.1

  3. Stage 1 & 2 Combined Secondary Objective: Progression-free survival (PFS) [ Time Frame: From start of treatment until documented PD or death. Assessed up to 2.5 years. ]
    Time from start of treatment to documented disease progression according to RECIST v 1.1, or death due to any cause

  4. Stage 1 & 2 Combined Secondary Objective: Overall survival (OS) [ Time Frame: From start of treatment until death. Assessed up to 2.5 years. ]
    Time from start of treatment to death

  5. Stage 1 & 2 Combined Secondary Objective: Maximum observed concentration [Cmax] [ Time Frame: Up to 5 cycles (46 weeks). ]
    PK parameters for duvelisib (and metabolite IPI-656) will be determined using bioanalytical data and Population PK (POPPK) modeling.

  6. Stage 1 & 2 Combined Secondary Objective: Area under the curve [AUC] [ Time Frame: Up to 5 cycles (46 weeks). ]
    PK parameters for duvelisib (and metabolite IPI-656) will be determined using bioanalytical data and POPPK modeling.

  7. Stage 1 & 2: Number of participants with treatment-emergent adverse events [ Time Frame: 24 months ]
    Number of participants with treatment-emergent adverse events as assessed by CTCAE v5.0



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Age ≥ 18 years, ECOG performance status ≤ 1
  • Histologically or cytologically-confirmed diagnosis of recurrent or metastatic head and neck squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx that is considered incurable by local therapies
  • Eligible for pembrolizumab monotherapy based on the current prescribing information for pembrolizumab (Keytruda 2019)
  • Must have had 0 to 2 prior therapies for R/M HNSCC.
  • At least 1 measurable lesion (which has not been previously irradiated) according to RECIST v 1.1
  • For stage 1 only: Must have at least 1 other lesion that can be biopsied and willing to undergo a pretreatment and on-treatment biopsy of the available tumor lesion
  • For stage 1 only: Must be willing to undergo a pretreatment and on-treatment biopsy of the available tumor lesion
  • Adequate organ function defined by the following laboratory parameters:
  • Absolute neutrophil count (ANC) ≥ 1.5 × 109/L
  • Platelet count ≥ 100 × 109/L
  • Hemoglobin level ≥ 9.0 g/dL
  • A serum creatinine level < 1.5 mg/dL, or
  • Estimated creatinine clearance value ≥ 60 mL/min (as determined by the Cockcroft-Gault method) for subjects with creatinine levels > 1.5 × institutional upper limit of normal (ULN)
  • Total bilirubin level ≤ 1.5 × ULN (exception: subjects with Gilbert's Syndrome may have a bilirubin level > 1.5 × ULN)
  • Aspartate aminotransaminase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum pyruvic transaminase (SGPT) levels ≤ 2.5 × ULN or ≤ 5 × ULN in subjects with liver metastases
  • International normalized ratio (INR) or prothrombin time (PT) and activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN, unless subject is receiving anticoagulant therapy in which case PT or aPTT must be within therapeutic range of intended use of anticoagulants

Exclusion Criteria

  • Previously treated with 3 or more systemic regimens given for recurrent and/or metastatic disease
  • Received anticancer treatment, major surgery, or any investigational drug within 30 days or 5 half-lives, whichever is shorter, before the start of study intervention
  • Received radiation therapy within 14 days before the start of study intervention, including, in addition (if necessary), the timeframe for resolution of any actual or anticipated toxicities from such radiation; Palliative radiation is allowed if > 7 days and any toxicity is ≤ Grade 1
  • Previous treatment with a PI3K, PD-1 or PD-L1 inhibitor
  • Have received organ or allogenic bone marrow or peripheral blood stem cell transplant
  • History of drug-induced colitis or drug-induced pneumonitis; history or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function; tuberculosis treatment within 2 years prior to the start of study intervention; chronic liver disease or veno-occlusive disease/sinusoidal obstruction syndrome
  • Active cytomegalovirus (CMV) or Epstein-Barr virus (EBV) infection; history of or known human immunodeficiency virus (HIV) infection
  • Ongoing treatment with chronic immunosuppressants or systemic steroids or treatment for systemic bacterial, fungal, or viral infection
  • Unable to receive prophylactic treatment for pneumocystis, herpes simplex virus (HSV), or herpes zoster (VZV) at screening
  • Concurrent administration of medications or foods that are strong inhibitors or inducers of cytochrome P450 3A (CYP3A). No prior use within 2 weeks before the start of study intervention Received a live or live attenuated vaccine within 6 weeks of first dose of duvelisib
  • Unable to receive prophylactic treatment for pneumocystis, herpes simplex virus (HSV), or herpes zoster (VZV) at screening
  • Any active gastrointestinal dysfunction interfering with the subject's ability to be administered oral medications
  • Known active central nervous system metastases and/or carcinomatous meningitis
  • QT interval > 500 ms (except for subjects with a right or left bundle branch block)
  • New York Heart Association Class III or IV congestive heart failure

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04193293


Locations
Layout table for location information
United States, Pennsylvania
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, United States, 15232
Sponsors and Collaborators
SecuraBio
Investigators
Layout table for investigator information
Study Director: David Cohan, MD SecuraBio Chief Medical Officer
Layout table for additonal information
Responsible Party: SecuraBio
ClinicalTrials.gov Identifier: NCT04193293    
Other Study ID Numbers: VS-0145-130
First Posted: December 10, 2019    Key Record Dates
Last Update Posted: March 17, 2021
Last Verified: March 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by SecuraBio:
Squamous Cell Carcinoma of the Head and Neck
Head and Neck Cancer
PI3K-δ,γ
PI3K Inhibitor
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Squamous Cell
Squamous Cell Carcinoma of Head and Neck
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell
Head and Neck Neoplasms
Neoplasms by Site
Pembrolizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents